Our Company
About us
About Xanamem
®
(emestedastat)
Xanamem® Pipeline
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
(emestedastat)
Mechanism of Action
The Cortisol Hypothesis
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Anxiety, sleep & behavioral problems in Fragile X Syndrome
Patient Portal
The XanaMIA Phase 2b/3 Alzheimer’s Trial
Publications
Investor Centre
News
Contact Us
Analyst Reports
Summary
Share Price
ASX Announcements
Press Releases
Corporate Presentations
Red Chip
All
2025
Spark Plus
2023
Bioshares
2024
2022
2021
2020
2019
2018
Baker Young
Bell Potter
Edison
NDF Research
Red Chip
Red Leaf Securities
Latest results
2024 Full Year Financial results
View Results Centre
2024 Annual General Meeting
Actinogen’s next Annual General Meeting
Date: 14 November 2024
Read more
Back
to top
